General Session 1
Prostate Cancer Diagnosis and Treatment of Localized Disease
|
|
|
| Introduction |
Neil Fleshner |
VIEW |
| MRI : Where do we stand in 2019? |
Masoom Haider |
VIEW |
| Biomarkers: From diagnosis to risk stratification |
Frédéric Pouliot |
VIEW |
| Active surveillance: Long term data. We continue to learn. |
Lawrence Klotz |
VIEW |
| Current radiotherapeutic approaches to treating localized disease |
Tamim Niazi |
VIEW |
| Treating M0 or nmCRPC |
Neil Fleshner |
VIEW |
| Discussion |
|
VIEW |
| |
|
|
General Session 2
Emerging Diagnostics and Therapies in Advance Prostate Cancer
|
|
|
| Introduction |
Sebastien Hotte |
VIEW |
| Theranostics and radioligands: Will this be the breakthrough? |
Himanshu Lukka and Katherine Zukotynski |
VIEW |
| Sequencing issues around ARPI |
Sebastien Hotte |
VIEW |
| Is there a Role for treating the primary in mCSPC? |
Robert Hamilton |
VIEW |
| |
|
|
Educational Forum
Swipe Right to Treat? Evaluating nmCRPC patient management strategies
|
|
|
| Swipe Right to Treat? Evaluating nmCRPC patient management strategies |
Sebastien Hotte and Bobby Shayegan |
VIEW |
| |
|
|
Podium Session 1
Advanced Prostate Cancer, Testes Cancer & Kidney Cancer
|
|
|
| Surgical castration in the management of metastatic prostate cancer: Current trends in androgen deprivation therapy |
Patrick Anderson |
VIEW |
| Factors associated with treatment completion and survival in patients with metastatic, castration-resistant prostate cancer undergoing radium-223 therapy in Ontario |
Sierra Cheng |
VIEW |
| Partial Orchiectomy: A review of the Princess Margaret Cancer Centre experience |
Greg Nason |
VIEW |
| Second cancer incidence and competing causes of death in patients with early stage Seminoma: A population-based study comparing radiation therapy versus chemotherapy |
Gaurav Bahl |
VIEW |
| |
|
|
Keynote 1
|
|
|
| Introduction |
Neil Fleshner |
VIEW |
| Keeping Pace with the Changing Treatment Landscape in Advanced Prostate Cancer |
Martin Gleave |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
Cases 1
|
|
|
| Canadian Clinical Cases |
Joseph Chin, Tamim Niazi and Alan So |
VIEW |
| |
|
|
General Session 3
Locally Advanced Kidney Cancer: Regional Node Dissection in Clinical Positive, Advanced RCC
|
|
|
| Introduction |
Tony Finelli |
VIEW |
| Lymph node dissection at the time of Nephrectomy - Con |
Luke Lavallée |
VIEW |
| |
|
|
Keynote 2
|
|
|
| Introduction |
Aly-Khan Lalani |
VIEW |
| Five-Year Outlook in The Management of Metastatic Urothelial Carcinoma |
Joaquim Bellmunt |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
Keynote 3
|
|
|
| Introduction |
Wassim Kassouf |
VIEW |
| Predicting Response to Immune Checkpoint Blockade in Bladder Cancer |
Thomas Powles |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
General Session 4
Potpourri of Bladder Cancer Research Across Canada (Ted Talk style)
|
|
|
| Introduction |
Wassim Kassouf |
VIEW |
| Optimization of surgical performance for radical cystectomy: Centralization of care and between-surgeon variation |
Adrian Fairey |
VIEW |
| Next gen oncolytic virus: Advancing intravesical bladder cancer therapy |
Ronald Moore |
VIEW |
| The search for a better biomarker |
Bernie Eigl |
VIEW |
| Photodynamic therapy for bladder cancer: Results of a phase Ib clinical trial |
Girish Kulkarni |
VIEW |
| Immune-checkpoint inhibition with radiation in bladder cancer: In situ and abscopal effects |
Wassim Kassouf |
VIEW |
| Molecular profiling in muscle invasive bladder cancer: More than the sum of its parts |
David Berman |
VIEW |
| Taking it up a NOTCH in bladder cancer |
Peter Black |
VIEW |
General Session 5
Debates on Controversial Topics in Urothelial Carcinoma
|
|
|
| Introduction |
Armen Aprikian |
VIEW |
| Open vs RARC |
Adrian Fairey |
VIEW |
| Open vs RARC |
Girish Kulkarni |
VIEW |
| Discussion |
|
VIEW |
| Neoadjuvant chemo for all MIBC vs Neoadjuvant chemotherapy guided by molecular subtyping |
Nimira Alimohamed |
VIEW |
| Neoadjuvant chemo for all MIBC vs Neoadjuvant chemotherapy guided by molecular subtyping |
Peter Black |
VIEW |
| Discussion |
|
VIEW |
| High grade UTUC: Neoadjuvant vs adjuvant chemotherapy |
Rodney Breau |
VIEW |
| |
|
|
Keynote 4
|
|
|
| Introduction |
Libni Eapen |
VIEW |
| Bladder Preservation for Invasive Bladder Cancer: Lessons Learned and Future Perspectives |
Robert Huddart |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
Cases 2
|
|
|
| Cases from the Multi-Disciplinary Clinic |
Rob Siemens (Chair), Alexandre Zlotta, Som Mukherjee and Peter Chung |
VIEW |
| |
|
|
Podium Session 2
Bladder Cancer & Other
|
|
|
| Introduction |
Michael Ong and Neil Fleshner |
VIEW |
| Clinical practice patterns of immediate intravesical chemotherapy following transurethral resection of bladder tumor in Canada |
Hamidreza Abdi |
VIEW |
| Are most patients >75 years old eligible for neoadjuvant chemotherapy prior to radical cystectomy? |
Aravinth Jebanesan |
VIEW |
| Neoadjuvant chemotherapy prior to bladder sparing chemoradiation for patients with muscle-invasive bladder cancer |
Di (Maria) Jiang |
VIEW |
| Robot-assisted radical cystectomy versus open radical cystectomy: A meta-analysis of oncologic, peri-operative and complication-related outcomes |
Christopher Wallis |
VIEW |
| Heterogeneity of immune checkpoint inhibitor response in advanced malignancies according to patient sex: A systematic review and meta-analysis of overall survival data |
Christopher Wallis |
VIEW |
| |
|
|
Keynote 5
|
|
|
| Introduction |
Rob Hamilton |
VIEW |
| Genomics in Uro-Oncology |
Paul Boutros |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
Keynote 6
|
|
|
| Introduction |
Neil Fleshner |
VIEW |
| Frailty in Older Adults With Urological Cancer: Why is it Important, and What Can We Do About it? |
Shabbir Alibhai |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
Keynote 7
|
|
|
| Introduction |
Kevin Zorn |
VIEW |
| New Horizons in the Management of Advanced Penile Cancer |
Philippe Spiess |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
Keynote 8
|
|
|
| Introduction |
Andy Evans |
VIEW |
| New Frontiers in Bladder Cancer: Genomics, Immunotherapy and More |
George Netto |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
General Session 6
mRCC: Evolution and Future
|
|
|
| Introduction |
Anil Kapoor |
VIEW |
| Cytoreductive Nephrectomy: Is there still a role for nephrectomy in patients with metastatic RCC? |
Ricardo Rendon |
VIEW |
| Biopsy of the small renal mass - Still controversial? |
Antonio Finelli |
VIEW |
| Questions and Answers |
|
VIEW |
| Biomarkers in mRCC: Too Cold, Too Hot, or Just Right? |
Aly-Khan Lalani |
VIEW |
| |
|
|
Keynote 9
|
|
|
| Introduction |
Anil Kapoor |
VIEW |
| Post IO Therapies: Sequencing in RCC in the IO Era |
Thomas Powles |
VIEW |
| Questions and Answers |
|
VIEW |
| |
|
|
Podium Session 3
Locally Advanced Prostate Cancer
|
|
|
| Introduction |
Neil Fleshner |
VIEW |
| Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of decipher and pam50 tests among different age groups |
Hanan Goldberg |
VIEW |
| Improving quality of prostate cancer surgery by providing feedback to surgeons: The Surgical Report card (SuRep) study |
Ravi Kumar |
VIEW |
| Expression of ERBB family members demonstrates a potential to predict prostate cancer progression |
Sylvie Clairefond |
VIEW |
| Personalized medicine tool to characterize treatment response in ex vivo tumor-derived prostate cancer samples |
Kayla Simeone |
VIEW |
| After low-dose-rate brachytherapy monotherapy, biochemical progression free survival is strongly influenced by the number of adverse prognostic features: An analysis of 4150 consecutive implants |
W. James Morris |
VIEW |
| |
|
|
General Session 7
High-Risk Prostate Cancer Debate: Radiation VS Surgery
|
|
|
| Introduction |
Neil Fleshner |
VIEW |
| High-Risk Prostate Cancer Debate: Radiation VS Surgery |
Gerard Morton |
VIEW |
| High-Risk Prostate Cancer Debate: Radiation VS Surgery |
Lawrence Klotz |
VIEW |
| Discussion |
|
VIEW |
| Closing Remarks |
Neil Fleshner, Aly-Khan Lalani, and Himu Lukka |
VIEW |
